Concomitant blockade of 5-HT 1A receptor and 5-HT transporter: Use of the Hunter Serotonin Toxicity Criteria in a clinical pharmacology study

European Neuropsychopharmacology

Volumn 22, Issue 2, 2012, Pages 92-99

  Parks, V ^a,c   Philipp, A W ^b   Raje, S ^c   Plotka, A ^c   Schechter, L E ^c   Connell, J ^d   Chalon, S ^a  

^a Clinical Research and Development   (France)

^b VasoTissue Technologies   (Germany)

^c PFIZER INC   (United States)

^d ICON Development Solutions   (United States)

Author keywords

Citalopram; Interaction; Lecozotan; Serotonin toxicity

Indexed keywords

CITALOPRAM; LECOZOTAN; PLACEBO; SEROTONIN 1A RECEPTOR; SEROTONIN TRANSPORTER;

ADULT; ARTICLE; ASTHENIA; BODY TEMPERATURE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPERSONALIZATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG SAFETY; DRUG WITHDRAWAL; EUPHORIA; HAND TREMOR; HEADACHE; HUMAN; HYPERREFLEXIA; INSOMNIA; LIBIDO; MALE; MUSCLE CRAMP; MUSCLE HYPERTONIA; MUSCLE SPASM; MUSCLE STIFFNESS; NAUSEA; NEUROTOXICITY; PARESTHESIA; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SIDE EFFECT; SOMNOLENCE; SWEATING; TIME TO MAXIMUM PLASMA CONCENTRATION; TINNITUS; TRISMUS; TWITCHING MOTILITY; VISION; XEROSTOMIA;

ADULT; BODY TEMPERATURE; CITALOPRAM; CROSS-OVER STUDIES; DIOXANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; ELECTROENCEPHALOGRAPHY; HUMANS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PIPERAZINES; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN 5-HT1 RECEPTOR ANTAGONISTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN SYNDROME; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84855201145     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2011.06.002     Document Type: Article

References (20)

1. Boyer E.W., Shannon M. The serotonin syndrome. N. Engl. J. Med. 2005, 352:1112-1120.
2. Brosen K., Naranjo C.A. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur. Neuropsychopharmacol. 2001, 11:275-283.
3. Childers W.E., Harrison B.L., Abou-Gharbia M.A., Raje S., Parks V., Pangalos M.N., Schechter L.E. Lecozotan hydrochloride. Drugs Future 2007, 32(5):399-407.
4. Dingemans J., Wallnöfer A., Gieschke R., Guentert T., Amrein R. Pharmacokinetic and pharmacodynamic interactions between fluoxetine and moclobemide in the investigation of the development of the "serotonin syndrome". Clin. Pharmacol. Ther. 1998, 63:403-413.
5. Dunkley E.J., Isbister G.K., Sibbritt D., Dawson A.H., Whyte I.M. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM 2003, 96:635-642.
6. Gillman P.K. The serotonin syndrome and its treatment. J. Psychopharmacol. 1999, 13(1):100-109.
7. Gutierrez M., Abramowitz W. Steady-state pharmacokinetics of citalopram in young and elderly subjects. Pharmacotherapy 2000, 20(12):1441-1447.
8. Herrlin K., Yasui-Furukori N., Tybring G. Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. Br. J. Clin. Pharmacol. 2003, 56:415-421.
9. Isbister G.K., Bowe S.J., Dawson A., Whyte I.M. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J. Toxicol. Clin. Toxicol. 2004, 42(3):277-285.
10. Isbister G.K., Buckley N.A., Whyte I.M. Serotonin toxicity: a practical approach to diagnosis and treatment. MJA 2007, 187:361-365.
11. Leuchter A.F., Lesser I.M., Trivedi M.H. An open pilot study of the combination of escitalopram and buproprion-SR for outpatients with major depressive disorder. J. Psychiatr. Pract. 2008, 14(5):271-280.
12. Lowe S.L., Yeo K.P., Teng L., Soon D., Pan A., Wise A., Peck R. L-5-Hydroxytryptophan augments the neuroendocrine response to a SSRI. Psychoneuroendocrinology 2006, 31:473-484.
13. Mason P.J., Morris V.A., Balcezak T.J. Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine 2000, 79:201-209.
14. Patat A., Parks V., Raje S., Plotka, Chassard D., Le Coz F. Safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of lecozotan in healthy young and elderly subjects. Br. J. Clin. Pharmacol. 2009, 67(3):299-308.
15. 1A antagonist, on cardiac repolarization in healthy adult subjects. Poster presented at the American College of Clinical Pharmacology (ACCP) September, 2008.
16. 1A receptors in healthy young and elderly subjects, and in patients with Alzheimer's disease. Clin. Pharm. Ther. 2008, 83(1):86-96.
17. Schechter L.E., et al. Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties. J. Pharmacol. Exp. Ther. 2005, 314:1274-1289.
18. Segrave R., Nathan P.J. Pindolol augmentation of selective serotonin reuptake inhibitors: accounting for the variability of results of placebo-controlled double-blind studies in patients with major depression. Hum. Psychopharmacol. 2005, 20:163-174.
19. Segrave R., Croft R.J., Illic S., Luan Phan K., Nathan P.J. Pindolol does not augment central serotonin function increases to citalopram in humans: an auditory evoked potential investigation. Pharmacol. Biochem. Behav. 2006, 85:82-90.
20. Yu B.N., Chen G.L., He N., et al. Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19. Drug Metab. Dispos. 2003, 31(10):1255-1259.